Fusen Pharma Unit to Raise 300 Million Yuan From State-Owned Investors
MT Newswires Live
Jun 19
Fusen Pharmaceutical (HKG:1652) said its unit, Henan Fusen Pharmaceutical, agreed to raise 300 million yuan through a capital increase from two state-owned investors, according to a Thursday Hong Kong bourse filing.
Nanyang Industrial Investment and Henan Xisheng will subscribe for newly issued equity representing about 34% of Henan Fusen's enlarged registered capital.
Following the transaction, Fusen Pharmaceutical's indirect stake in the unit will decrease to about 66%, while the unit will remain a subsidiary.
The proceeds will be used mainly to repay debt and replenish working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.